Fibrocell Science (FCSC) 7.48 $FCSC
Fibrocell to Present at 2015 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Tue Aug 04, 7:00AM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, Chairman and Chief Executive Officer, will present at the 2015 Wedbush PacGrow Healthcare Conference at 8:00 am EDT on Tuesday, August 11, 2015 in New York City.
FCSC: 7.48 (+0.83), XON: 68.71 (+3.37)
Fibrocell to Report Second Quarter 2015 Financial and Operating Results, and Host Conference Call and Webcast on Thursday, August 6, 2015
GlobeNewswire - Thu Jul 30, 7:01AM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, will report second quarter 2015 results on Thursday, August 6, 2015, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its second quarter 2015 financial and operational results. A question-and-answer session will follow Fibrocell's remarks.
FCSC: 7.48 (+0.83), XON: 68.71 (+3.37)
Fibrocell prices public offering at USD5.80 per share
M2 - Thu Jul 23, 4:35AM CDT
Gene therapy company Fibrocell Science (NasdaqCM:FCSC) said on Wednesday that it has priced its public offering of 2.6m shares of its common stock.
FCSC: 7.48 (+0.83)
Why Shares of Fibrocell Science Jumped Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jul 22, 11:55AM CDT
What: Shares of Fibrocell Science , a clinical stage gene-therapy company with a focus on rare skin and tissue diseases, jumped more than 10% today after the company released pricing details of their recently-announced secondary stock offering. ...
FCSC: 7.48 (+0.83)
Fibrocell Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jul 22, 8:00AM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, today announced the pricing of an underwritten public offering of 2.6 million shares of its common stock at a price of $5.80 per share. In addition, Fibrocell has granted the underwriters a 30-day option to purchase up to an additional 0.4 million shares of common stock.
FCSC: 7.48 (+0.83)
Fibrocell to issue common stock in public offering
M2 - Wed Jul 22, 4:43AM CDT
Gene therapy company Fibrocell Science (NasdaqCM:FCSC) reported on Tuesday that it has commenced its public offering of its common stock as part of its existing shelf registration statement.
FCSC: 7.48 (+0.83)
Fibrocell Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jul 21, 3:01PM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, today announced that it has commenced an underwritten public offering of its common stock pursuant to its existing shelf registration statement. All of the shares in the offering are to be sold by Fibrocell.
FCSC: 7.48 (+0.83), XON: 68.71 (+3.37)
Fibrocell Science and Intrexon partnership submits IND Application to the US FDA for FCX-007 for treating recessive dystrophic epidermolysis bullosa
M2 - Tue Jul 21, 5:06AM CDT
Gene therapy company Fibrocell Science (NasdaqCM:FCSC) disclosed on Monday the submission of an Investigational New Drug (IND) Application with the US Food and Drug Administration for its lead orphan gene-therapy drug candidate FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) in partnership with
Fibrocell to Present at 2015 Wedbush PacGrow Healthcare Conference
GlobeNewswire - Tue Aug 04, 7:00AM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, Chairman and Chief Executive Officer, will present at the 2015 Wedbush PacGrow Healthcare Conference at 8:00 am EDT on Tuesday, August 11, 2015 in New York City.
FCSC: 7.48 (+0.83), XON: 68.71 (+3.37)
Fibrocell to Report Second Quarter 2015 Financial and Operating Results, and Host Conference Call and Webcast on Thursday, August 6, 2015
GlobeNewswire - Thu Jul 30, 7:01AM CDT
Fibrocell Science, Inc. (NASDAQ:FCSC), an autologous cell and gene therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, will report second quarter 2015 results on Thursday, August 6, 2015, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its second quarter 2015 financial and operational results. A question-and-answer session will follow Fibrocell's remarks.
FCSC: 7.48 (+0.83), XON: 68.71 (+3.37)
Fibrocell prices public offering at USD5.80 per share
M2 - Thu Jul 23, 4:35AM CDT
Gene therapy company Fibrocell Science (NasdaqCM:FCSC) said on Wednesday that it has priced its public offering of 2.6m shares of its common stock.
FCSC: 7.48 (+0.83)
Why Shares of Fibrocell Science Jumped Today
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jul 22, 11:55AM CDT
What: Shares of Fibrocell Science , a clinical stage gene-therapy company with a focus on rare skin and tissue diseases, jumped more than 10% today after the company released pricing details of their recently-announced secondary stock offering. ...
FCSC: 7.48 (+0.83)
Fibrocell Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Jul 22, 8:00AM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, today announced the pricing of an underwritten public offering of 2.6 million shares of its common stock at a price of $5.80 per share. In addition, Fibrocell has granted the underwriters a 30-day option to purchase up to an additional 0.4 million shares of common stock.
FCSC: 7.48 (+0.83)
Fibrocell to issue common stock in public offering
M2 - Wed Jul 22, 4:43AM CDT
Gene therapy company Fibrocell Science (NasdaqCM:FCSC) reported on Tuesday that it has commenced its public offering of its common stock as part of its existing shelf registration statement.
FCSC: 7.48 (+0.83)
Fibrocell Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Jul 21, 3:01PM CDT
Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, today announced that it has commenced an underwritten public offering of its common stock pursuant to its existing shelf registration statement. All of the shares in the offering are to be sold by Fibrocell.
FCSC: 7.48 (+0.83), XON: 68.71 (+3.37)
Fibrocell Science and Intrexon partnership submits IND Application to the US FDA for FCX-007 for treating recessive dystrophic epidermolysis bullosa
M2 - Tue Jul 21, 5:06AM CDT
Gene therapy company Fibrocell Science (NasdaqCM:FCSC) disclosed on Monday the submission of an Investigational New Drug (IND) Application with the US Food and Drug Administration for its lead orphan gene-therapy drug candidate FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) in partnership with
